GAMMA Investing’s Lifecore Biomedical LFCR Stock Holding History

GAMMA Investing’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$520	Sell	79 -37	-32%	-$172	﹤0.01%	4205
2026 Q2	$609	Sell	116 -138	-54%	-$695	﹤0.01%	3956
2026 Q1	$945	Sell	254 -339	-57%	-$2.34K	﹤0.01%	3849
2025 Q4	$4.85K	Buy	593 +81	+16%	+$599	﹤0.01%	3293
2025 Q3	$3.77K	Sell	512 -79	-13%	-$598	﹤0.01%	3276
2025 Q2	$4.8K	Buy	591 +84	+17%	+$566	﹤0.01%	3138
2025 Q1	$3.57K	Buy	507 +323	+176%	+$2.01K	﹤0.01%	3220
2024 Q4	$1.37K	Buy	184 +30	+19%	+$192	﹤0.01%	3333
2024 Q3	$759	Buy	+154	New	+$805	﹤0.01%	3321

Other funds holding LFCR

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's LFCR Position: Q3 2026 in Review

GAMMA Investing reduced its Lifecore Biomedical (LFCR) stake by 32% in Q3 2026, selling an estimated $172 and leaving 79 shares worth $520. The position accounts for ﹤0.01% of the portfolio, ranked #4205.

GAMMA Investing first reported a position in LFCR in Q3 2024 and has held it in 9 quarters since. The position peaked at $4.85K in Q4 2025. 3 funds tracked by Wall St. Rank hold LFCR as of Q3 2026.

GAMMA Investing held 79 shares of Lifecore Biomedical worth $520 as of Q3 2026.
GAMMA Investing sold 37 Lifecore Biomedical shares in Q3 2026, an estimated $172.
Lifecore Biomedical made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4205 holding.
GAMMA Investing first reported a position in Lifecore Biomedical in Q3 2024 and has held it in 9 quarters since.
GAMMA Investing's Lifecore Biomedical position peaked at $4.85K in Q4 2025.
3 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.